NBP insider transaction filings
NovaBridge Biosciences — 10 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-10. Screen NBP transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4 | Hagler Mark Arnold — Chief Commercial Officer | Grant/award (A): 949,050 (derivative) @ $0 | EDGAR |
| 2026-07-10 | 4 | Lin Liwei Lorraine — General Counsel | Grant/award (A): 254,780 (derivative) @ $0 | EDGAR |
| 2026-07-08 | 4 | Gupta Srishti — Chief Executive Officer, Director | Grant/award (A): 3,000,000 (derivative) @ $0 | EDGAR |
| 2026-07-07 | 4 | Xu Cong Claire — SVP, Clinical Development | Option exercise (M): 12,432 · Sale (S): 4,485 @ $0.89 · Option exercise (M): 5,405 (derivative) @ $0 | EDGAR |
| 2026-06-30 | 4 | Fu Wei — Director | Grant/award (A): 725,140 (derivative) @ $0 · Grant/award (A): 1,087,720 (derivative) @ $0 · Grant/award (A): 1,087,720 (derivative) @ $0 · Grant/award (A): 1,010,100 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Cao Sean Wuxiong — Chief Bus. Development Officer, Director | Grant/award (A): 181,280 (derivative) @ $0 · Grant/award (A): 181,290 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Dennis Phillip Andrew — Chief Medical Officer | Option exercise (M): 23,695 · Sale (S): 8,494 @ $0.66 · Option exercise (M): 10,302 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | Xu Cong Claire — SVP, Clinical Development | Option exercise (M): 9,382 · Sale (S): 3,494 @ $3.94 · Option exercise (M): 4,079 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Cao Sean Wuxiong — See Remarks, Director | Sale (S): 21,399 @ $1.99 | EDGAR |
| 2026-04-28 | 4 | Hagler Mark Arnold — See Remarks | Purchase (P): 230,000 @ $2.51 | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=NBP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →